Global Acute Myeloid Leukemia Drugs Market Insights, Research, Forecast to 2025

Published On: Aug 2019

Format: PDF

Publisher: QY Research

Pages: 110

Report ID: 47926

Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age.
The global Acute Myeloid Leukemia Drugs market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Acute Myeloid Leukemia Drugs market based on company, product type, end user and key regions.

This report studies the global market size of Acute Myeloid Leukemia Drugs in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Acute Myeloid Leukemia Drugs in these regions.
This research report categorizes the global Acute Myeloid Leukemia Drugs market by top players/brands, region, type and end user. This report also studies the global Acute Myeloid Leukemia Drugs market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Ambit Biosciences Corporation
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals

Market size by Product
DC regimen
AVD Regimen
VCD regimen
Market size by End User
Hospital
Clinic
Others

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Acute Myeloid Leukemia Drugs market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Acute Myeloid Leukemia Drugs market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Acute Myeloid Leukemia Drugs companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Acute Myeloid Leukemia Drugs submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Acute Myeloid Leukemia Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Acute Myeloid Leukemia Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
1.1 Acute Myeloid Leukemia Drugs Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Acute Myeloid Leukemia Drugs Market Size Growth Rate by Product
1.4.2 DC regimen
1.4.3 AVD Regimen
1.4.4 VCD regimen
1.5 Market by End User
1.5.1 Global Acute Myeloid Leukemia Drugs Market Size Growth Rate by End User
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Others
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Acute Myeloid Leukemia Drugs Market Size
2.1.1 Global Acute Myeloid Leukemia Drugs Revenue 2014-2025
2.1.2 Global Acute Myeloid Leukemia Drugs Sales 2014-2025
2.2 Acute Myeloid Leukemia Drugs Growth Rate by Regions
2.2.1 Global Acute Myeloid Leukemia Drugs Sales by Regions
2.2.2 Global Acute Myeloid Leukemia Drugs Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Acute Myeloid Leukemia Drugs Sales by Manufacturers
3.1.1 Acute Myeloid Leukemia Drugs Sales by Manufacturers
3.1.2 Acute Myeloid Leukemia Drugs Sales Market Share by Manufacturers
3.1.3 Global Acute Myeloid Leukemia Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Acute Myeloid Leukemia Drugs Revenue by Manufacturers
3.2.1 Acute Myeloid Leukemia Drugs Revenue by Manufacturers (2014-2019)
3.2.2 Acute Myeloid Leukemia Drugs Revenue Share by Manufacturers (2014-2019)
3.3 Acute Myeloid Leukemia Drugs Price by Manufacturers
3.4 Acute Myeloid Leukemia Drugs Manufacturing Base Distribution, Product Types
3.4.1 Acute Myeloid Leukemia Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Acute Myeloid Leukemia Drugs Product Type
3.4.3 Date of International Manufacturers Enter into Acute Myeloid Leukemia Drugs Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Acute Myeloid Leukemia Drugs Sales by Product
4.2 Global Acute Myeloid Leukemia Drugs Revenue by Product
4.3 Acute Myeloid Leukemia Drugs Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Acute Myeloid Leukemia Drugs Breakdown Data by End User

6 North America
6.1 North America Acute Myeloid Leukemia Drugs by Countries
6.1.1 North America Acute Myeloid Leukemia Drugs Sales by Countries
6.1.2 North America Acute Myeloid Leukemia Drugs Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Acute Myeloid Leukemia Drugs by Product
6.3 North America Acute Myeloid Leukemia Drugs by End User

7 Europe
7.1 Europe Acute Myeloid Leukemia Drugs by Countries
7.1.1 Europe Acute Myeloid Leukemia Drugs Sales by Countries
7.1.2 Europe Acute Myeloid Leukemia Drugs Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Acute Myeloid Leukemia Drugs by Product
7.3 Europe Acute Myeloid Leukemia Drugs by End User

8 Asia Pacific
8.1 Asia Pacific Acute Myeloid Leukemia Drugs by Countries
8.1.1 Asia Pacific Acute Myeloid Leukemia Drugs Sales by Countries
8.1.2 Asia Pacific Acute Myeloid Leukemia Drugs Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Acute Myeloid Leukemia Drugs by Product
8.3 Asia Pacific Acute Myeloid Leukemia Drugs by End User

9 Central & South America
9.1 Central & South America Acute Myeloid Leukemia Drugs by Countries
9.1.1 Central & South America Acute Myeloid Leukemia Drugs Sales by Countries
9.1.2 Central & South America Acute Myeloid Leukemia Drugs Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Acute Myeloid Leukemia Drugs by Product
9.3 Central & South America Acute Myeloid Leukemia Drugs by End User

10 Middle East and Africa
10.1 Middle East and Africa Acute Myeloid Leukemia Drugs by Countries
10.1.1 Middle East and Africa Acute Myeloid Leukemia Drugs Sales by Countries
10.1.2 Middle East and Africa Acute Myeloid Leukemia Drugs Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Acute Myeloid Leukemia Drugs by Product
10.3 Middle East and Africa Acute Myeloid Leukemia Drugs by End User

11 Company Profiles
11.1 Ambit Biosciences Corporation
11.1.1 Ambit Biosciences Corporation Company Details
11.1.2 Company Business Overview
11.1.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Ambit Biosciences Corporation Acute Myeloid Leukemia Drugs Products Offered
11.1.5 Ambit Biosciences Corporation Recent Development
11.2 Celgene Corporation
11.2.1 Celgene Corporation Company Details
11.2.2 Company Business Overview
11.2.3 Celgene Corporation Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Celgene Corporation Acute Myeloid Leukemia Drugs Products Offered
11.2.5 Celgene Corporation Recent Development
11.3 Cephalon
11.3.1 Cephalon Company Details
11.3.2 Company Business Overview
11.3.3 Cephalon Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Cephalon Acute Myeloid Leukemia Drugs Products Offered
11.3.5 Cephalon Recent Development
11.4 Clavis Pharma
11.4.1 Clavis Pharma Company Details
11.4.2 Company Business Overview
11.4.3 Clavis Pharma Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Clavis Pharma Acute Myeloid Leukemia Drugs Products Offered
11.4.5 Clavis Pharma Recent Development
11.5 Eisai
11.5.1 Eisai Company Details
11.5.2 Company Business Overview
11.5.3 Eisai Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.5.4 Eisai Acute Myeloid Leukemia Drugs Products Offered
11.5.5 Eisai Recent Development
11.6 Genzyme Corporation
11.6.1 Genzyme Corporation Company Details
11.6.2 Company Business Overview
11.6.3 Genzyme Corporation Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Genzyme Corporation Acute Myeloid Leukemia Drugs Products Offered
11.6.5 Genzyme Corporation Recent Development
11.7 Sunesis Pharmaceuticals
11.7.1 Sunesis Pharmaceuticals Company Details
11.7.2 Company Business Overview
11.7.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Sunesis Pharmaceuticals Acute Myeloid Leukemia Drugs Products Offered
11.7.5 Sunesis Pharmaceuticals Recent Development

12 Future Forecast
12.1 Acute Myeloid Leukemia Drugs Market Forecast by Regions
12.1.1 Global Acute Myeloid Leukemia Drugs Sales Forecast by Regions 2019-2025
12.1.2 Global Acute Myeloid Leukemia Drugs Revenue Forecast by Regions 2019-2025
12.2 Acute Myeloid Leukemia Drugs Market Forecast by Product
12.2.1 Global Acute Myeloid Leukemia Drugs Sales Forecast by Product 2019-2025
12.2.2 Global Acute Myeloid Leukemia Drugs Revenue Forecast by Product 2019-2025
12.3 Acute Myeloid Leukemia Drugs Market Forecast by End User
12.4 North America Acute Myeloid Leukemia Drugs Forecast
12.5 Europe Acute Myeloid Leukemia Drugs Forecast
12.6 Asia Pacific Acute Myeloid Leukemia Drugs Forecast
12.7 Central & South America Acute Myeloid Leukemia Drugs Forecast
12.8 Middle East and Africa Acute Myeloid Leukemia Drugs Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Acute Myeloid Leukemia Drugs Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer